PE20061350A1 - DERIVATIVES OF 5H-BENZOCICLOHEPTENO, PROCEDURES FOR THEIR PREPARATION AND USE AS ANTI-INFLAMMATORY - Google Patents

DERIVATIVES OF 5H-BENZOCICLOHEPTENO, PROCEDURES FOR THEIR PREPARATION AND USE AS ANTI-INFLAMMATORY

Info

Publication number
PE20061350A1
PE20061350A1 PE2006000307A PE2006000307A PE20061350A1 PE 20061350 A1 PE20061350 A1 PE 20061350A1 PE 2006000307 A PE2006000307 A PE 2006000307A PE 2006000307 A PE2006000307 A PE 2006000307A PE 20061350 A1 PE20061350 A1 PE 20061350A1
Authority
PE
Peru
Prior art keywords
alkyl
benzociclohepten
tetrahydro
hydroxy
dimethyl
Prior art date
Application number
PE2006000307A
Other languages
Spanish (es)
Inventor
Hartmut Rehwinkel
Duy Nguyen
Heike Schacke
Markus Berger
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of PE20061350A1 publication Critical patent/PE20061350A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIERE A COMPUESTOS DE 5H-BENZOCICLOHEPTENOS DE FORMULA (I) DONDE R1 Y R2 SON INDEPENDIENTEMENTE H, HIDROXI, HALOGENO, ALQUILO(C1-C10), CIANO, -CF3, ENTRE OTROS; R11Y R12 SON H; R3 ES ALQUILO(C1-C10), FENILO OPCIONALMENTE SUSTITUIDOS, HETEROARILO MONO- O BICICLICO QUE CONTIENE DE 1 A 3 ATOMOS DE N, Y/O O U S, OPCIONALMENTE SUSTITUIDOS CON CETO, ALQUILO(C1-C5), ENTRE OTROS , TAL COMO FTALIDILO, ISOINDOLILO, DIHIDROISOINDOLILO, ENTRE OTROS; A ES -CR6R7-CH2- O -CH2-CR6R7- DONDE R6 Y R7 SON H, METILO, ETILO O JUNTO CON EL CARBONO DE 5H-BENZOCICLOHEPTENO SON UN ANILLO CICLOALQUILO(C3-C6); D ES -CR4R5-CH2- O -CH2-CR4R5- DONDE R4 ES HIDROXI, ENTRE OTROS Y R5 ES ALQUILO(C1-C5) OPCIONALMENTE FLUORADO, CICLOALQUILO(C3-C7), ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 1-BROMO-6,7,8,9-TETRAHIDRO-5-[(1H-INDAZOL-4-IL)AMINO]-8,8-DIMETIL-6-(TRIFLUOROMETIL)-5H-BENZOCICLOHEPTEN-6-OL, 4-{[1-BROMO-6,7,8,9-TETRAHIDRO-6-HIDROXI-8,8-DIMETIL-6-(TRIFLUOROMETIL)-5H-BENZOCICLOHEPTEN-5-IL]AMINO}-1,3-DIHIDRO-2H-INDOL-2-ONA, 2-CLORO-6,7,8,9-TETRAHIDRO-5-(1H-INDAZOL-4-ILAMINO)-8,8-DIMETIL-6-(TRIFLUOROMETIL)-5H-BENZOCICLOHEPTEN-6-OL, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS INHIBEN LA SECRECION DE LA CITOQUINA IL-8 PROVOCADA POR LIPOPOLISACARIDOS (LPS) SIENDO UTILES EN EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS TALES COMO ASMA BRONQUIAL, ARTRITIS REUMATOIDEA, DERMATITIS ATOPICA, PSORIASISREFERS TO COMPOUNDS OF 5H-BENZOCYCLOHEPTENES OF FORMULA (I) WHERE R1 AND R2 ARE INDEPENDENTLY H, HYDROXY, HALOGEN, ALKYL (C1-C10), CYANE, -CF3, AMONG OTHERS; R11 AND R12 ARE H; R3 IS ALKYL (C1-C10), OPTIONALLY SUBSTITUTED PHENYL, MONO- OR BICYCLIC HETEROARYL, CONTAINING 1 TO 3 N ATOMS, AND / OOUS, OPTIONALLY SUBSTITUTED WITH CETUS, ALKYL (C1-C5), BETWEEN OTHERS , ISOINDOLYL, DIHYDROISOINDOLYL, AMONG OTHERS; A IS -CR6R7-CH2- OR -CH2-CR6R7- WHERE R6 AND R7 ARE H, METHYL, ETHYL OR TOGETHER WITH THE CARBON OF 5H-BENZOCICLOHEPTENO IS A CYCLOALKYL RING (C3-C6); D IS -CR4R5-CH2- OR -CH2-CR4R5- WHERE R4 IS HYDROXY, AMONG OTHERS AND R5 IS ALKYL (C1-C5) OPTIONALLY FLUORATED, CYCLOALKYL (C3-C7), AMONG OTHERS. THE PREFERRED COMPOUNDS ARE: 1-BROMO-6,7,8,9-TETRAHYDRO-5 - [(1H-INDAZOL-4-IL) AMINO] -8,8-DIMETHYL-6- (TRIFLUOROMETIL) -5H-BENZOCICLOHEPTEN-6 -OL, 4 - {[1-BROMO-6,7,8,9-TETRAHYDRO-6-HYDROXY-8,8-DIMETHYL-6- (TRIFLUORomethyl) -5H-BENZOCICLOHEPTEN-5-IL] AMINO} -1, 3-DIHYDRO-2H-INDOL-2-ONA, 2-CHLORO-6,7,8,9-TETRAHYDRO-5- (1H-INDAZOL-4-ILAMINO) -8,8-DIMETHYL-6- (TRIFLUOROMETHYL) - 5H-BENZOCICLOHEPTEN-6-OL, AMONG OTHERS. IT ALSO REFERS TO A PREPARATION PROCEDURE AND A PHARMACEUTICAL COMPOSITION. SUCH COMPOUNDS INHIBIT THE SECRETION OF CYTOKINE IL-8 CAUSED BY LIPOPOLYSACCHARIDES (LPS), BEING USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES SUCH AS BRONCHIAL ASTHMA, RHEUMATOID ARTHRITIS, ATOPIC DERMATITIS, PSORIASIS

PE2006000307A 2005-03-22 2006-03-21 DERIVATIVES OF 5H-BENZOCICLOHEPTENO, PROCEDURES FOR THEIR PREPARATION AND USE AS ANTI-INFLAMMATORY PE20061350A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005014090A DE102005014090A1 (en) 2005-03-22 2005-03-22 5H-Benzocycloheptender derivatives, process for their preparation and their use as anti-inflammatory agents

Publications (1)

Publication Number Publication Date
PE20061350A1 true PE20061350A1 (en) 2006-12-20

Family

ID=36589218

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000307A PE20061350A1 (en) 2005-03-22 2006-03-21 DERIVATIVES OF 5H-BENZOCICLOHEPTENO, PROCEDURES FOR THEIR PREPARATION AND USE AS ANTI-INFLAMMATORY

Country Status (13)

Country Link
EP (1) EP1863765A1 (en)
JP (1) JP2008534462A (en)
CN (1) CN101146773A (en)
AR (1) AR053189A1 (en)
CA (1) CA2598969A1 (en)
DE (1) DE102005014090A1 (en)
DO (1) DOP2006000065A (en)
GT (1) GT200600124A (en)
PA (1) PA8666801A1 (en)
PE (1) PE20061350A1 (en)
TW (1) TW200700389A (en)
UY (1) UY29435A1 (en)
WO (1) WO2006100099A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA038639B1 (en) * 2016-02-15 2021-09-28 Санофи 6,7-dihydro-5h-benzo[7]annulene derivatives as estrogen receptor modulators
CN107118173B (en) * 2017-07-12 2019-10-29 阿里生物新材料（常州）有限公司 A kind of cycloheptatriene and oxazine compound and preparation method thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8402275A (en) * 1974-08-26 1977-02-17 Takeda Chemical Industries Ltd Benzocycloheptene derivatives
AU617672B2 (en) * 1987-05-15 1991-12-05 Schering Corporation Aryl substituted naphthalene, benzoxepine, benzazepine, benzocycloheptene derivatives
ATE145907T1 (en) * 1987-07-16 1996-12-15 Byk Gulden Lomberg Chem Fab IMIDAZO(1,2-A>PYRIDINE
CA2297910A1 (en) * 1997-07-25 1999-02-04 Smithkline Beecham Corporation Vitronectin receptor antagonist
MXPA05007937A (en) * 2003-02-07 2005-09-30 Warner Lambert Co Oxazolidinone derivatives n-substituted by a bicyclic ring, for use as antibacterial agents.

Also Published As

Publication number Publication date
EP1863765A1 (en) 2007-12-12
CN101146773A (en) 2008-03-19
DOP2006000065A (en) 2006-10-15
AR053189A1 (en) 2007-04-25
CA2598969A1 (en) 2006-09-28
UY29435A1 (en) 2006-10-02
JP2008534462A (en) 2008-08-28
DE102005014090A1 (en) 2006-09-28
TW200700389A (en) 2007-01-01
GT200600124A (en) 2007-01-03
PA8666801A1 (en) 2006-09-22
WO2006100099A1 (en) 2006-09-28

Similar Documents

Publication Publication Date Title
PE20081776A1 (en) 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR
PE20120058A1 (en) IMIDAZOPYRAZINE DERIVATIVES AS SYK INHIBITORS
PE20200016A1 (en) SUBSTITUTE DIAZABICYCLIC IMIDAZOPYRIMIDINES AND THEIR USE FOR THE TREATMENT OF RESPIRATORY DISORDERS
PE20110545A1 (en) TRIAZOLOPYRIDINE COMPOUNDS AS JAK INHIBITORS
TW201129565A (en) Tricyclic heterocyclic compounds, compositions and methods of use thereof
EA200801001A1 (en) COMPOUNDS WHICH HAVE ACTIVITY WITH RESPECT TO M RECEPTORS, AND THEIR APPLICATIONS IN MEDICINE
PE20151249A1 (en) PYRAZOLOPYRIMIDINE DERIVATIVES AS INHIBITORS OF JAK KINASES
PE20090960A1 (en) QUINAZOLINADIONE DERIVATIVES, ITS PREPARATION AND THEIR THERAPEUTIC APPLICATIONS
PE20060604A1 (en) TETRAHYDRONAPHTHALENE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS AND PROCEDURE FOR THEIR PREPARATION
NZ597994A (en) Nitrogen-containing spiro-ring compound and medicinal use of same
AR080785A1 (en) DERIVATIVES OF IMIDAZO [1,2-A] PYRIMIDINE, PROCESS TO PREPARE THEM AND INTERMEDIARIES OF SUCH SYNTHESIS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE OF THEM IN THE TREATMENT OF PATHOLOGIES OF THE CENTRAL NERVOUS SYSTEM, SUCH AS PARK AND OTHERS.
CL2011002115A1 (en) Compounds derived from 5-phenyl-1h-pyridin-2-one and 5-phenyl-pyrazin-2-one, bruton tyrosine kinase inhibitors (btk); process of preparation of the compounds, intermediate compound, pharmaceutical composition and use in the treatment of inflammatory and / or autoimmune diseases.
TW200745004A (en) Novel compounds, their preparation and use
PE20091734A1 (en) 2-IMINO-3-METHYLPYRROLOPYRIMIDINONE PHENYL-SUBSTITUTED COMPOUNDS AS BACE-1 INHIBITORS, COMPOSITIONS AND THEIR USE
PE20080274A1 (en) DERIVATIVES OF DIOXO-ALKANES AND DIOXO-ALKENES REPLACED AS MODULATORS OF THE VANILLOID RECEPTOR SUBTYPE 1 (TRPV1)
CL2007001711A1 (en) Compounds derived from substituted pyrazolopyridine; pharmaceutical composition comprising them; method of preparation of the compounds, intermediates; and their use in the treatment of diseases, such as tumors, rheumatoid arthritis, diseases of deregulated vascular growth, among others.
AR078833A1 (en) DERIVATIVES OF HETEROARILOS CONTAINING NITROGEN AS INHIBITORS OF THE CINASA JAK3
AR077463A1 (en) IMIDAZO DERIVATIVES [1, 2 - A] PIRAZINA AND ITS USE IN MEDICINES FOR THE TREATMENT OF PARASITARY DISEASES
AR086100A1 (en) CHROMENONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
EA201170374A1 (en) Derivatives of substituted tricyclic acids as agonists of the S1P1 receptor, used in the treatment of autoimmune and inflammatory diseases
EA201101566A1 (en) IMIDAZOL DERIVATIVES AND THEIR APPLICATION AS CYLIN-dependent KINAZ MODULATORS
PE20090333A1 (en) SUBSTITUTE OXAZOLIDINONES AND THEIR USE
EA201390010A1 (en) SUBSTITUTED TRIAZOLOPIRIDINES
HK1142604A1 (en) Quinolines and their therapeutic use
GEP20146063B (en) Solid pharmaceutical composition

Legal Events

Date Code Title Description
FA Abandonment or withdrawal